45 results on '"Belshe, Robert"'
Search Results
2. A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066)
3. Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples
4. Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine
5. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects
6. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009–2010 seasonal trivalent influenza vaccinations
7. Phase II randomized, double-blinded comparison of a single high dose (5 × 108 TCID50) of modified vaccinia Ankara compared to a standard dose (1 × 108 TCID50) in healthy vaccinia-naïve individuals
8. Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age
9. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States
10. Clinical and immunologic responses to multiple doses of IMVAMUNE ® (Modified Vaccinia Ankara) followed by Dryvax ® challenge
11. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects
12. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines
13. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults
14. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3 cp45) among susceptible infants and toddlers
15. Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection
16. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults
17. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans
18. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1 SF-2 recombinant GP120
19. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control
20. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses
21. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies
22. Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity
23. Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals
24. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario
25. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
26. The need for quadrivalent vaccine against seasonal influenza
27. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
28. Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine
29. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin
30. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity
31. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects
32. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults
33. Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
34. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers
35. Letter to the Editor
36. Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120
37. Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein
38. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva
39. Acellular pertussis vaccines in infants: evaluation of single component and two-component products
40. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins
41. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160
42. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults
43. Modulation of immunologic responses to HIV-1 MN recombinant gp160 vaccine by dose and schedule of administration
44. Phase II randomized, double-blinded comparison of a single high dose (5×108 TCID50) of modified vaccinia Ankara compared to a standard dose (1×108 TCID50) in healthy vaccinia-naïve individuals.
45. Live attenuated intranasal influenza vaccine.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.